Overview
Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs.
Dr. Hann is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.
Her clinical research consists of co-authoring 91 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Olfactory Neuroblastoma.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, Baltimore, MD 21224
201 North Broadway Street, Viragh BLDG 5th FL, Baltimore, MD 21287
10803 Falls Road, Pavilion III STE 1500, Lutherville, MD 21093
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
6 Clinical Trials
Charalampos Floudas is an Oncologist in Bethesda, Maryland. Dr. Floudas is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Olfactory Neuroblastoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Gliomatosis Cerebri.
University Of Maryland Oncology Associates PA
Kevin Cullen is an Oncologist in Baltimore, Maryland. Dr. Cullen is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Olfactory Neuroblastoma, Teratocarcinosarcoma, and Laryngeal Cancer. Dr. Cullen is currently accepting new patients.
Mgmc LLC
Geoffrey Gibney is a Hematologist and an Oncologist in Washington, Washington, D.c.. Dr. Gibney is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Olfactory Neuroblastoma, and Sinus Cancer.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Lung CancerDr. Hann isElite. Learn about Lung Cancer.
- Small Cell Lung Cancer (SCLC)
- Distinguished
- ALK-Positive Non-Small Cell Lung CancerDr. Hann isDistinguished. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- EGFR Positive Lung CancerDr. Hann isDistinguished. Learn about EGFR Positive Lung Cancer.
- Large-Cell Lung CarcinomaDr. Hann isDistinguished. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Hann isDistinguished. Learn about Lung Adenocarcinoma.
- Neuroendocrine TumorDr. Hann isDistinguished. Learn about Neuroendocrine Tumor.
- Non-Small Cell Lung Cancer (NSCLC)Dr. Hann isDistinguished. Learn about Non-Small Cell Lung Cancer (NSCLC).
- Advanced
- ChordomaDr. Hann isAdvanced. Learn about Chordoma.
- Familial Pancreatic CancerDr. Hann isAdvanced. Learn about Familial Pancreatic Cancer.
- Pancreatic CancerDr. Hann isAdvanced. Learn about Pancreatic Cancer.
- Experienced
- AgranulocytosisDr. Hann isExperienced. Learn about Agranulocytosis.
- AnemiaDr. Hann isExperienced. Learn about Anemia.
- AstrocytomaDr. Hann isExperienced. Learn about Astrocytoma.
- Brain TumorDr. Hann isExperienced. Learn about Brain Tumor.
- DehydrationDr. Hann isExperienced. Learn about Dehydration.
- Embryonal Tumor with Multilayered Rosettes